Methods for the treatment and prevention of lung infections caused by SARS-CoV-2 virus by administration of tafenoquine
Methods and composition for treating or preventing a lung infection, or related symptoms, caused by a virus using an effective amount of tafenoquine are disclosed. Methods and compositions for treating or preventing a lung infection in a human that is infected with SARS-CoV-2 using tafenoquine are disclosed. Kits including tafenoquine and means for testing for a viral infection are disclosed.
1 . A method of treating a coronavirus infection and/or a disease resulting therefrom in a human subject, the method comprising:
(a) identifying a human subject that is infected with said coronavirus and/or suffering from said disease resulting therefrom; and
(b) administering to said human subject tafenoquine, a pharmaceutically-acceptable salt thereof, or a pharmaceutical composition comprising tafenoquine, wherein the tafenoquine, the pharmaceutically-acceptable salt thereof, or the pharmaceutical composition comprising tafenoquine is administered at an effective amount to treat at least one symptom of the coronavirus infection and/or the disease resulting therefrom, and
wherein the coronavirus is any variant of SARS-CoV-2 and/or the disease resulting therefrom is COVID-19.
2 . The method according to claim 1 , wherein said effective amount comprises 600 mg administered over one to three days.
3 . The method according to claim 1 , wherein said effective amount comprises 800 mg administered over one to four days.
4 . The method according to claim 1 , wherein about 100 to about 800 mg of tafenoquine, the pharmaceutically-acceptable salt thereof, or the pharmaceutical composition comprising tafenoquine is administered in one or more initial dose(s) and in one or more subsequent dose(s).
5 . The method according to claim 1 , wherein an initial dose of about 100 to 800 mg over one to four days is administered and then at least one dose of approximately 100 to 400 mg is administered once weekly.
6 . The method according to claim 1 , wherein at least one and up to 4 weekly doses of approximately 100 to 400 mg is administered following an initial dose of 100 to 800 mg.
7 . A method of preventing a coronavirus infection and/or a disease resulting therefrom in a human subject, the method comprising:
administering to said human subject an effective amount of tafenoquine a pharmaceutically-acceptable salt thereof, or a pharmaceutical composition comprising tafenoquine and wherein the coronavirus is any variant of SARS-CoV-2 and/or the disease resulting therefrom is COVID-19.
8 . The method according to claim 7 , wherein said effective amount comprises 600 mg administered over one to three days.
9 . The method according to claim 7 , wherein said effective amount comprises 800 mg administered over one to four days.
10 . The method according to claim 7 , wherein about 100 to about 800 mg of tafenoquine, the pharmaceutically-acceptable salt thereof, or the pharmaceutical composition comprising tafenoquine is administered in one or more initial dose(s) and in one or more subsequent dose(s).
11 . The method according to claim 7 , wherein an initial dose of about 100 to 800 mg over one to four days is administered and then at least one dose of approximately 100 to 400 mg is administered once weekly.
12 . The method according to claim 7 , in which at least one and up to 51 weekly doses of approximately 100 to 400 mg is administered following an initial dose of 100 to 800 mg.
13 . A method of pre-treating a coronavirus infection and/or a disease resulting therefrom in a human subject, the method comprising:
administering to said human subject an effective amount of tafenoquine, a pharmaceutically-acceptable salt thereof, or a pharmaceutical composition comprising tafenoquine, and
wherein the coronavirus is any variant of SARS-CoV-2 and/or the disease resulting therefrom is COVID-19.
14 . The method according to claim 13 , wherein said effective amount comprises 600 mg administered over one to three days,
wherein at least the first administration is prior to exposure or potential exposure to SARS-CoV-2.
15 . The method according to claim 13 , wherein said effective amount comprises 800 mg administered over one to four days, wherein at least the first administration is prior to exposure or potential exposure to SARS-CoV-2.
16 . The method according to claim 13 , wherein about 100 to about 800 mg of tafenoquine, the pharmaceutically-acceptable salt thereof, or the pharmaceutical composition comprising tafenoquine is administered in one or more initial dose(s) and in one or more subsequent dose(s).
17 . The method according to claim 13 , wherein about 100 to 800 mg is administered over one to four days and then at least one dose of approximately 100 to 400 mg is administered weekly.
18 . The method according to claim 13 , in which at least one and up to 51 weekly doses of approximately 100 to 400 mg is administered following an initial dose of 100 to 800 mg.
19 . The method according to claim 1 , further comprising administering a second agent for treating or preventing a bacterial, a fungal, and/or a viral infection.
20 . The method according to claim 1 , wherein the effective amount comprises administering 200 mg daily for three consecutive days and then administering one dose of 200 mg six to eight days after the third dose.